Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 69-76

  Yao, James C ^a   Lombard Bohas, Catherine ^a   Baudin, Eric ^a   Kvols, Larry K ^a   Rougier, Philippe ^a   Ruszniewski, Philippe ^a   Hoosen, Sakina ^a   St Peter, Jessica ^a   Haas, Tomas ^a   Lebwohl, David ^a   Van Cutsem, Eric ^a   Kulke, Matthew H ^a   Hobday, Timothy J ^a   O'Dorisio, Thomas M ^a   Shah, Manisha H ^a   Cadiot, Guillaume ^a   Luppi, Gabriele ^a   Posey, James A ^a   Wiedenmann, Bertram ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; EVEROLIMUS; NEURON SPECIFIC ENOLASE; OCTREOTIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENOLASE; RAPAMYCIN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APHTHOUS STOMATITIS; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OPEN STUDY; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; SIROLIMUS; TREATMENT FAILURE;

EID: 73949088959     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.2669     Document Type: Article

References (36)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
2. Yao JC, Eisner MP, Leary C, et al: Population-based study of islet cell carcinoma. Ann Surg Oncol 14:3492-3500, 2007
3. Lam KY, Lo CY: Pancreatic endocrine tumour: A 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 23:36-42, 1997
4. Solorzano CC, Lee JE, Pisters PW, et al: Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery 130:1078-1085, 2001
5. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroentero-pancreatic system. Ann Oncol 15:966-973, 2004
6. Saltz L, Trochanowski B, Buckley M, et al: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72:244-248, 1993
7. Arnold R, Müller H, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009 (abstr 121)
8. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762-4771, 2004
9. Delaunoit T, Ducreux M, Boige V, et al: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: A judicious option? Eur J Cancer 40:515-520, 2004
10. Broder LE, Carter SK: Pancreatic islet cell carcinoma: II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108-118, 1973
11. Chernicoff D, Bukowski RM, Groppe CW Jr, et al: Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat Rep 63:795-796, 1979
12. Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189-1194, 1980
13. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
14. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006
15. Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986-2991, 2007
16. Kulke MH, Stuart K, Earle CC, et al: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24:189s, 2006 (suppl; abstr 4044)
17. Jensen RT, Berna MJ, Bingham DB, et al: Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113:1807-1843, 2008 (suppl 7)
18. Yao JC: Neuroendocrine tumors: Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21:163-172, 2007
19. von Wichert G, Jehle PM, Hoeflich A, et al: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60:4573-4581, 2000
20. Hörsch D, Tielke S, Schrader J: Expression and activation of mTOR in neuroendocrine tumors: Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signaling in neuroendocrine cell lines. J Clin Oncol 25:582s, 2007 (suppl; abstr 10570)
21. Moreno A, Akcakanat A, Munsell MF, et al: Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15:257-266, 2008
22. Boulay A, Zumstein-Mecker S, Stephan C, et al: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261, 2004
23. Torres-Arzayus MI, Yuan J, Della Gatta JL, et al: Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Res 66:11381-11388, 2006
24. Haritunians T, Mori A, O'Kelly J, et al: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333-339, 2007
25. Yao JC, Phan AT, Chang DZ, et al: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II trial. J Clin Oncol 26:4311-4318, 2008
26. Panzuto F, Di Fonzo M, Iannicelli E, et al: Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17:461-466, 2006
27. Arnold R, Rinke A, Klose KJ, et al: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 3:761-771, 2005
28. Hobday T, Holen K, Donehower R, et al: A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A phase II consortium (P2C) study. J Clin Oncol 24:189s, 2006 (suppl; abstr 4043)
29. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
30. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
31. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
32. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
33. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006
34. Pollak MN, Polychronakos C, Guyda H: Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9:889-891, 1989
35. O'Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
36. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008